The journal of obstetrics and gynaecology research · 2025
The effect of esketamine on perioperative anxiety and depressive symptoms in patients undergoing total hysterectomy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ding Jinfeng, Yang Yanqing, Cao Donghang, Wang Tingting, Yu Qimin
Аннотация
AIM: This study aimed to evaluate the effect of esketamine on perioperative anxiety and depressive symptoms, acute stress reaction, and serum neurotransmitters in patients undergoing total hysterectomy.
METHODS: Clinical data of 120 patients undergoing total hysterectomy from May 2020 to June 2021 were retrospectively analyzed and divided into group C (3 mL of saline administered intravenously 10 min before surgical excision, 65 patients) or group K (0.5 mg/kg of esketamine administered intravenously 10 min before surgical excision, 55 patients).
RESULTS: Acute stress reaction, depression, and anxiety; and myeloperoxidase levels were lower while serum dopamine, 5-hydroxytryptamine, neuropeptide, as well as brain-derived neurotrophic factor levels were higher in group K than those in group C at 12 h postoperatively (p < 0.05). Additionally, analgesic effect and postoperative fatigue at 3 h and 12 h postoperatively were lower in group K than those in group C (p < 0.05). The incidence of adverse reactions in group K (14.55%) did not differ significantly from group C (4.62%) (p > 0.05).
CONCLUSIONS: In summary, as a preventive measure for patients undergoing total hysterectomy, esketamine can reduce perioperative anxiety and depression, result in good analgesic and sedative effects without significantly increasing adverse effects.
METHODS: Clinical data of 120 patients undergoing total hysterectomy from May 2020 to June 2021 were retrospectively analyzed and divided into group C (3 mL of saline administered intravenously 10 min before surgical excision, 65 patients) or group K (0.5 mg/kg of esketamine administered intravenously 10 min before surgical excision, 55 patients).
RESULTS: Acute stress reaction, depression, and anxiety; and myeloperoxidase levels were lower while serum dopamine, 5-hydroxytryptamine, neuropeptide, as well as brain-derived neurotrophic factor levels were higher in group K than those in group C at 12 h postoperatively (p < 0.05). Additionally, analgesic effect and postoperative fatigue at 3 h and 12 h postoperatively were lower in group K than those in group C (p < 0.05). The incidence of adverse reactions in group K (14.55%) did not differ significantly from group C (4.62%) (p > 0.05).
CONCLUSIONS: In summary, as a preventive measure for patients undergoing total hysterectomy, esketamine can reduce perioperative anxiety and depression, result in good analgesic and sedative effects without significantly increasing adverse effects.